Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17415625 | 0.94 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL13862617 | 0.94 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL29893236 | 0.94 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL1539477 | 0.94 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL1539482 | 0.94 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL1539561 | 0.94 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL20473222 | 0.93 | KDM4E (0.34) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL20473229 | 0.91 | KDM4E (0.34) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL20473271 | 0.90 | KDM4E (0.33) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL19006567 | 0.90 | MAPT (0.33) | KDM4EMEN1NPC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253983-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-20190175613-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LIMITED (GB) | 2019-06-13 | — | — | US | disclosed |
| US-10000464-B2 | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiazepine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process | PAION UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170044135-A1 | PROCESS FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(2-PYRIDINYL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPINE-4-YL]PROPIONIC ACID METHYL ESTER OR THE BENZENE SULFONATE SALT THEREOF, AND COMPOUNDS USEFUL IN THAT PROCESS | PAION UK LIMITED (GB) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175613-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | GABARAP, GABRP, GABRA5 | KDM4E 2180/4885MEN1 2407/4885NPC1 789/4885 |
| US-10000464-B2 | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-A][1,4]benzodiazepine-4-yl]propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process | GABRA1, CYP2F1, GABRA6 | KDM4E 250/4885MEN1 2478/4885NPC1 3385/4885 |
| US-20170044135-A1 | PROCESS FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(2-PYRIDINYL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPINE-4-YL]PROPIONIC ACID METHYL ESTER OR THE BENZENE SULFONATE SALT THEREOF, AND COMPOUNDS USEFUL IN THAT PROCESS | GABRA1, CYP2F1, GABRA6 | KDM4E 250/4885MEN1 2478/4885NPC1 3385/4885 |
| US-20200253983-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | GABARAP, GABRP, GABRA5 | KDM4E 2180/4885MEN1 2407/4885NPC1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.